May 4, 2017 at 11 am PT/2 pm ET


Webinar: 23andMe’s New FDA-Authorized Health Reports

Register to watch on demand (43 minutes)

Earlier this month, the FDA authorized 23andMe to provide genetic risk information for certain health conditions, including AATD, late-onset Alzheimer’s disease and more.

Studies show that many consumers want to know their genetic health risk even for conditions that have no current prevention or treatments,1 and that about 30% of people who get over-the-counter (OTC) genetic testing share their results with healthcare providers.2,3,4

As genetic health information becomes more accessible to consumers—23andMe has genotyped more than 2 million people—your patients are more likely to discuss genetic health risks with you.

Watch this 23andMe webinar to learn about the new Genetic Health Risk reports*, including the science behind our tests and how genetic risk information is communicated to consumers. The webinar features 23andMe’s Shirley Wu, PhD, Director of Product Science, and Stacey Detweiler, MS, LCGC, Genetic Counselor and Medical Affairs Associate.

This webinar is intended for healthcare professionals, though it is open to educators, researchers, students and lifelong learners.

View sample reports and package inserts for Genetic Health Risk reports.

About the speakers:

Stacey Detweiler, MS, LCGC, is a licensed and board certified genetic counselor with 4 years of clinical and research experience in perinatal genetics. She is also an active member of the National Society of Genetic Counselors. Stacey joined 23andMe in 2016 as a Medical Affairs Associate and focused on product, clinical, and educational development. In her previous roles, Stacey served as both a perinatal genetic counselor and clinical research coordinator at Rutgers-Robert Wood Johnson Medical School. She also continued her work as a perinatal genetic counselor providing direct patient care at Palo Alto Medical Foundation.

Shirley Wu, PhD, leads the team of PhD scientists responsible for researching, critically evaluating, and writing 23andMe’s health reports. She received her B.S. in Computational Biology from Brown University and her PhD in Biomedical Informatics from Stanford University working with Dr. Russ Altman. Shirley joined 23andMe in 2009 as a Curation Scientist and took on roles at the intersection of product development, scientific critique, regulatory affairs, quality assurance, and science communication. Serving as head of 23andMe’s scientific product team since 2010, Shirley is committed to maintaining rigorous scientific standards, making an accessible and compassionate product experience, and providing information that engages individuals towards better health and wellness.

  1. Roberts J, Ostergren J. Direct-to-Consumer Genetic Testing and Personal Genomics Services: A Review of Recent Empirical Studies. Current Genetic Medicine Reports 2013;1(3):182-200.

  2. Darst, Burcu F. et al. “Characteristics Of Genomic Test Consumers Who Spontaneously Share Results With Their Health Care Provider.” Health Communication 29.1 (2013): 105-108.

  3. Roberts, J. Scott, and Jenny Ostergren. “Direct-To-Consumer Genetic Testing And Personal Genomics Services: A Review Of Recent Empirical Studies.” Current Genetic Medicine Reports1.3 (2013): 182-200.

  4. van der Wouden, Cathelijne H. et al. “Consumer Perceptions Of Interactions With Primary Care Providers After Direct-To-Consumer Personal Genomic Testing.” Annals of Internal Medicine164.8 (2016): 513.


*The 23andMe PGS test uses qualitative genotyping to detect clinically relevant variants in the genomic DNA of adults from saliva collected using an FDA-cleared collection device (Oragene·DX model OGD-500.001) for the purpose of reporting and interpreting genetic health risks. It is not intended to diagnose any disease. The relevance of each report varies based on ethnicity. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. These reports are intended to provide genetic information that can be used to inform lifestyle decisions and conversations with healthcare professionals, but are not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication or how much of a medication you should take. Any diagnostic or treatment decisions should be based on testing or other information deemed appropriate by a healthcare professional. 

For important information and limitations regarding other genetic health risk reports and carrier status reports, visit

Webinar Question and Answer